Rhythm Pharmaceuticals, Inc 8-K/A, filed Jan 4, 2021
Rhythm Pharmaceuticals, Inc. (RYTM)
About this 8-K/A
Rhythm Pharmaceuticals, Inc filed this 8-K/A on January 4, 2021, reporting on events of December 31, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name
of each exchange on which registered | ||
(Nasdaq Global Market) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On December 11, 2020, Rhythm Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K disclosing that the Company’s Board of Directors (the “Board”) had appointed Lynn A. Tetrault and Camille L. Bedrosian, M.D. as directors of the Company. At the time of that filing, the Board had not determined on which Board committees Ms. Tetrault or Dr. Bedrosian would serve. On December 31, 2020, the Board appointed Ms. Tetrault to the Compensation Committee of the Board, and Dr. Bedrosian to the Governance and Nominating Committee of the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RHYTHM PHARMACEUTICALS, INC. | ||
| Date: January 4, 2021 | By: | /s/ Hunter Smith |
| Hunter Smith | ||
| Chief Financial Officer | ||
2